Advertisement

Topics

Shire shifts vaccine facility from Baxalta deal to MSD

04:35 EDT 8 Aug 2017 | Pharmafile

As part of Shire’s mega-merger with Baxalta, it suddenly had a massive manufacturing network that spanned 17 sites across seven countries. It was inevitable that the company had to consolidate or sell off some of these sites to make it a more manageable prospect.

It continued this process by selling its Austria-based vaccine plant to MSD for an undisclosed fee. The 340,000-square-foot facility holds the capability to manufacture vaccines and had been used as a storage facility for another part of its vaccine manufacturing network in Austria.

read more

Original Article: Shire shifts vaccine facility from Baxalta deal to MSD

NEXT ARTICLE

More From BioPortfolio on "Shire shifts vaccine facility from Baxalta deal to MSD"

Quick Search
Advertisement
 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...